Key result
Ischemic preconditioning reduces infarct volume ~79% via adenosine without requiring alpha-adrenergic activation.
Why the study?
The study aimed to determine whether adrenergic activation is cardioprotective, whether this protection involves adenosine receptor activation, and whether ischemic preconditioning requires alpha-adrenergic activation.
Does adrenergic activation or ischemic preconditioning reduce infarct volume via adenosine or alpha-adrenergic receptors in a rabbit model of ischemia-reperfusion?
Does adrenergic activation or ischemic preconditioning reduce infarct volume via adenosine or alpha-adrenergic receptors in a rabbit model of ischemia-reperfusion?
Cardioprotection from ischemic preconditioning and alpha-adrenergic activation both involve adenosine, but ischemic preconditioning does not require alpha-adrenergic activation.
Answers are grounded in this paper and cite their sources.
Ischemic preconditioning's adenosine-dependent protection in rabbits extends mechanistic insights; clinical translation remains untested.
BACKGROUND: The aim of this study was to determine whether (1) adrenergic activation is cardioprotective, (2) adrenergic cardioprotection occurs via adenosine receptor activation, and (3) ischemic preconditioning requires alpha-adrenergic activation. METHODS: Anesthetised open chest rabbits underwent 30 min coronary occlusion and 3 h reperfusion. Ischemic preconditioning was elicited with 5 min coronary occlusion and 10 min reperfusion. Activation of adrenergic receptors with endogenous norepinephrine was achieved with tyramine (0.28 mg/kg/min intravenously for 5 min). Adenosine receptors were blocked with 8-p-sulfophenyl theophylline (10 mg/kg intravenously), alpha 1-adrenergic receptors were selectively blocked with prazosin (0.1 mg/kg intravenously), and alpha-adrenergic receptors were blocked with phentolamine (4 mg/kg intravenously). RESULTS: Ischemic preconditioning reduced risk-adjusted infarct volume by 79% (P < 0.0005). This protection was attenuated by adenosine receptor blockade. Tyramine infusion resulted in a 1305% change from baseline plasma norepinephrine concentration (P < or = 0.01), and reduced infarct volume by 55% (P = 0.01). Adenosine receptor blockade abolished this protection. Blockade of alpha 1-adrenergic receptors with prazosin failed to abolish ischemic preconditioning (79 versus 89% reduction in infarct volume, without and with prazosin, respectively). Similarly, non-selective blockade of alpha-adrenergic receptors also failed to abolish ischemic preconditioning (79 versus 57% reduction without and with phentolamine, respectively). CONCLUSIONS: We conclude that the cardioprotection of ischemic preconditioning and alpha-adrenergic activation both involve adenosine, but ischemic preconditioning does not require alpha-adrenergic activation.
No takes yet. Share an insight, caveat, or question.
Haessler et al. (1996) studied Myocardial infarction. Ischemic preconditioning and adrenergic activation (tyramine) vs. Control (no preconditioning/activation) was evaluated on Risk-adjusted infarct volume (79% reduction, p=< 0.0005). Ischemic preconditioning reduced risk-adjusted infarct volume by 79%, a cardioprotective effect that involves adenosine but does not require alpha-adrenergic activation.
Synapse has enriched 10 related papers. Consider them for comparative context: